Wall Street analysts expect Arch Therapeutics Inc (NASDAQ:ARTH) to announce ($0.01) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Arch Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.01) and the lowest estimate coming in at ($0.02). Arch Therapeutics also reported earnings per share of ($0.01) during the same quarter last year. The company is expected to issue its next quarterly earnings report on Monday, December 4th.

According to Zacks, analysts expect that Arch Therapeutics will report full year earnings of ($0.05) per share for the current fiscal year, with EPS estimates ranging from ($0.06) to ($0.04). For the next financial year, analysts expect that the company will post earnings of ($0.03) per share, with EPS estimates ranging from ($0.05) to $0.00. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that cover Arch Therapeutics.

ARTH has been the subject of several research reports. HC Wainwright set a $3.00 price objective on Arch Therapeutics and gave the company a “buy” rating in a report on Thursday, July 27th. Zacks Investment Research raised Arch Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 price objective for the company in a report on Tuesday, October 17th. ValuEngine raised Arch Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 26th. Finally, Ifs Securities reissued an “outperform” rating on shares of Arch Therapeutics in a report on Tuesday, July 25th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $2.31.

Shares of Arch Therapeutics (NASDAQ ARTH) traded down $0.03 during midday trading on Tuesday, reaching $0.63. The company’s stock had a trading volume of 666,869 shares, compared to its average volume of 322,176. Arch Therapeutics has a 1-year low of $0.41 and a 1-year high of $0.89.

ILLEGAL ACTIVITY WARNING: “-$0.01 Earnings Per Share Expected for Arch Therapeutics Inc (ARTH) This Quarter” was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/11/14/0-01-earnings-per-share-expected-for-arch-therapeutics-inc-arth-this-quarter.html.

Arch Therapeutics Company Profile

Arch Therapeutics, Inc is a development-stage company. The Company operates as a biotechnology company. The Company focuses on developing products to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. The Company’s technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids.

Get a free copy of the Zacks research report on Arch Therapeutics (ARTH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Arch Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.